当前位置: X-MOL 学术Cancer Cell › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
Cancer Cell ( IF 50.3 ) Pub Date : 2020-05-11 , DOI: 10.1016/j.ccell.2020.04.007
Peter Savas 1 , Sherene Loi 2
Affiliation  

PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.

中文翻译:

扩大免疫疗法在三阴性乳腺癌中的作用。

PD-1轴阻滞结合化学疗法可改善PD-L1阳性的晚期三阴性乳腺癌的预后。现在,KEYNOTE-522的3期临床试验表明,与PD-L1状态无关,将pembrolizumab加入化疗可提高病理学完全缓解率,并且似乎可以提高生存率。
更新日期:2020-05-11
down
wechat
bug